TBIQYR4278-Global Amifostine Market Research Report 2019

                                          
Amifostine (Ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed by Clinigen Group under the trade name Ethyol.
Amifostine is a pro-drug which is activated to the free thiol metabolite at the tissue site. The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells.

Consumption of amifostine mainly concentrates in North America. In 2016, the region consumed 780 K Unit, holding about 52% market share globally. The follower is Asia-Pacific, with about 41% consumption share.

The market is relatively concentrated and there are just a few suppliers in the market, such as Clinigen Group, Sun Pharmaceutical, Merro Pharmaceutical and so on. Clinigen Group acquired the business from AstraZeneca in the year of 2014 and signed an agreement with Cumberland in the year of 2016. Under the agreement, Cumberland acquired the exclusive rights to commercialize Ethyol in the United States. Merro Pharmaceutical own the largest sales share in China.

Amifostine shows good effect in reducing harmful effects of cisplatin chemotherapy on kidneys in women treated for advanced ovarian cancer as well as relieving dry mouth problems (xerostomia) with head and neck cancer patients undergoing radiation treatment. It is estimated that the amifostine market will keep upward tendency and to be worthy of 49.99 million USD in 2023 globally.


The global Amifostine market is valued at 48 million US$ in 2018 is expected to reach 57 million US$ by the end of 2025, growing at a CAGR of 2.2% during 2019-2025.
This report focuses on Amifostine volume and value at global level, regional level and company level. From a global perspective, this report represents overall Amifostine market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Clinigen Group
    Sun Pharmaceutical
    Taj Pharmaceuticals
    Merro Pharmaceutical
    Luye Pharma
    Mingren Pharma
    ...

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    400mg/Dose
    500mg/Dose

Segment by Application
    Head and Neck Cancer Adjuvant Therapy
    Others